ARCHIVES

Scientific Opportunity Should Guide Fund Allocation, House Says

This article is from The Cancer Letter archive.

Vol. 21 No. 31 | August 4, 1995

Download PDF Visit The Full Archive

Related Articles

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

June 28, 2013

DCT Board reluctantly Okays Resources Contracts Recompetition, $6 of $10 Million Competitively

April 1, 1977

FDA Policy On Support Of Medical Education Near Final Form

February 5, 1993

Study Examines Lung Cancer Among Lifelong Nonsmokers

October 31, 2008

In Brief: Breast Cancer Diet Study Problems Resolved, Funding Resumed For Nutrition Coordinator

April 19, 1985

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

March 8, 2002